More importantly, FACS analysis for the CD44-CD24 markers (Figure 5D) revealed that administration of the LSD1 inhibitor resulted in a significant reduction in the number of tumor CSCs (CD44+CD24-/low), compared to tumors before treatment initiation and to vehicle-treated ones (Figure 5E). This evidence concerns the gene KDM1A and neoplasm.